US researchers have reported that the modernized vaccine Moderna vaccine for the “coded virus 19”, showed that it was safe and triggered immune responses in all 45 healthy volunteers, in an ongoing study at an early stage, according to Reuters.
The team reported in the New England Journal of Medicine, that volunteers who received two doses of the vaccine had high levels of antibodies to kill the Corona virus that exceeded the average levels seen in people who recovered from the Corona virus.COVID-19“.
Reuters said that no volunteers in the study experienced serious side effects, but more than half reported mild or moderate reactions, such as fatigue, headache, chills, muscle aches, or pain at the injection site, that were more likely to occur. This is after the second dose, and in people who have received a higher dose.
Experts added that a vaccine is needed to end the coronavirus, which has killed millions and killed 575,000 people worldwide, noting that Moderna was the first to start the human test of the new Coronavirus vaccine on March 16..
Dr. Anthony Fossey, director of the National Institute of Allergy and Infectious Diseases, whose researchers developed the Moderna vaccine candidate, described the results as “good news”, noting that the study did not find any serious negative events, and that the vaccine produced “reasonably high” levels that killed viruses or neutralized Antibodies.
And Dr. “Fossy” added in a telephone interview: “If the vaccine can cause a similar response to the natural infection, then this is the winner.” That is why we are happy with the results. “ .
The US government supports the Moderna vaccine, with nearly half a billion dollars, and has chosen it as one of the first to have had extensive human trials..
Moderna injection is used, mRNA-1273 , Ribonucleic acid (RNA) When injected into humans, the vaccine directs cells to produce proteins that mimic the outer surface of the coronavirus, which the body recognizes as foreign or alien invaders, and carries an immune response against it. The results published on Tuesday included 3 doses of the vaccine, tested in Groups of 15 volunteers, ages 18 to 55, received two doses, a difference of 28 days, groups tested 25, 100, or 250 micrograms of the vaccine.
In the higher-dose group, the Reuters report added, 3 patients had severe reactions such as fever, chills, headache, and nausea.
“We have not seen any complications described as serious negative,” said Dr. Lisa Jackson of the Kaiser Permanente Institute of Health Research in Washington, referring to reactions that require hospitalization or lead to death..
In June, Moderna said it had chosen a dose of 100 micrograms, to reduce harmful reactions, with that dose, explaining It is on track to provide about 500 million doses annually, and possibly up to one billion doses annually, starting in 2021, from the company’s internal manufacturing site to the US, and strategic cooperation with the Swiss pharmaceutical company Lonza
“It is a good first step,” said Dr. William Schavner, a vaccine expert at Vanderbilt University Medical Center, who was not involved in the study..
In April, Moderna expanded its first phase of vaccine to protect against the Corona virus, to include adults older than 55 years who are at greater risk of developing serious diseases, with the goal of registering 120 volunteers.
The company confirmed, it will follow the volunteers of the study for a year, to search for side effects, and to verify the duration of the immunity period, as the company started its experiment in the second stage in May, and it is expected that the third phase experience will start on July 27.
The first stage experiments aim to ensure that the treatment is safe, and help determine an effective dose. The second stage trials test the treatment in a larger group and get an early reading about the effectiveness. The third stage trials are conducted in a large group of individuals to confirm the effectiveness and identify rare side effects, will be conducted Experience the third phase of Moderna in 30,000 volunteers.